As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
|Videos|November 12, 2022
Examining Tophus Reduction in the MIRROR Trial, with John Botson, MD, RPh, CCD
An expert rheumatologist provides an overview of the MIRROR trial and the reduction in tophus observed among patients with gout included in the trial.
Advertisement
Advertisement
Related to this article
Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Facial and total body repigmentation with upadacitinib kept rising through Week 76 in Viti-Up, with higher responses when NB-UVB was added.
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
The first controlled study of GLP-1 receptor agonists and nail health found nail detachment in 39% of users versus 9% of controls at EADV 2026.
Earlier bimekizumab treatment was tied to higher IHS4-100 rates at 3 years in hidradenitis suppurativa, per post hoc BE HEARD data at EADV 2026.
Advertisement
Advertisement
Trending on HCPLive
1
US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD
2
Nail Detachment 4 Times More Common With GLP-1 Use
3
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes
4
FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM
5